Regulus Therapeutics Inc.·4

May 21, 4:39 PM ET

Deeg Mark Albert 4

4 · Regulus Therapeutics Inc. · Filed May 21, 2018

Insider Transaction Report

Form 4
Period: 2018-05-17
Deeg Mark Albert
Chief Medical Officer
Transactions
  • Award

    Common Stock (Right to Buy)

    2018-05-17+100,000100,000 total
    Exercise: $0.71Exp: 2028-05-16Common Stock (100,000 underlying)
Footnotes (1)
  • [F1]The option will vest in forty-eight equal monthly installments, such that the option will be fully vested four years from the date of grant, subject to the Reporting Person's continuous service to us.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION